Today, ACRO announced that its Board of Directors elected Cassandra “Sandy” Kennedy, Chief Quality, Regulatory Affairs, and ...

Clinical research company Fortrea Holdings (NASDAQ:FTRE) announced better-than-expected revenue in Q3 CY2025, with sales up 3.9% year on year to $701.3 million. The company’s full-year revenue ...

The 8 drug development inputs & services stocks we track reported a strong Q3. As a group, revenues beat analysts’ consensus estimates by 2.9%. Luckily, drug development inputs & services stocks have ...

Fortrea is down 30.8% since the beginning of the year, and at $12.91 per share, it is trading 45.6% below its 52-week high of $23.73 from December 2024. Investors who bought $1,000 worth of Fortrea’s ...

Fortrea Holdings recently completed a debt tender offer to repurchase US$75.74 million of its 7.500% Senior Secured Notes due 2030, reducing the outstanding principal in connection with earlier ...

DURHAM, N.C., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it has completed its debt tender ...

DURHAM, N.C. - Fortrea (NASDAQ:FTRE) has completed its debt tender offer by purchasing $75,743,000 of its outstanding 7.500% Senior Secured Notes due 2030, the clinical research organization announced ...

The live webcasts and replay of the fireside chats will be accessible through the“Events” section of Fortrea's Investor Relations website. Investors interested in one-on-one meetings should contact ...

DURHAM, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced the appointment of Agnieszka (Aggie) M.